

Prostate cancer treatment: An encouraging combination therapy

November 3 2021



Credit: Unsplash/CC0 Public Domain

A trio of drugs could delay the progression of metastatic castration-

resistant prostate cancer.

This is among the findings of a phase III clinical trial published in *The Lancet Oncology* by an international research team led by Dr. Fred Saad, a researcher at the CHUM Research Centre, a Université de Montréal professor and the holder of the Raymond Garneau Chair in Prostate Cancer Research.

The result of a collaboration with 167 hospitals in 17 countries, this study, called ACIS, identified for the first time a combination of three types of drugs said to slow the progression of metastases by more than 7 months. This is a significant therapeutic breakthrough for this difficult-to-treat disease, which is still fatal today.

Giving more time

To get these results, the international team recruited 982 men between the end of 2014 and the middle of 2016 and divided them randomly into two groups (randomized, [double-blind trial](#)). Of the volunteers, 492 received apalutamide (an anti-androgen) combined with abiraterone (an androgen synthesis inhibitor) and prednisone (an anti-inflammatory drug); 490 others received only abiraterone and prednisone.

This well-tolerated therapeutic trio was administered to patients with metastatic castration-resistant [prostate cancer](#). Prostate cancer is considered castration-resistant when the cancer progresses despite hormone therapy.

By following the progression of the cancer through radiology, the scientists were able to show that the men in the first group lived 24 months (median) without signs of disease progression, compared to 16.6 months for those in the second group.

Additional studies will be needed to accurately identify the sub-categories of patients who would most benefit from this new treatment for metastatic castration-resistant [prostate](#) cancer.

The article "Apalutamide plus [abiraterone acetate](#) and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate [cancer](#) (ACIS): a randomized, placebo-controlled, double-blind, multinational, phase 3 study" by Dr. Fred Saad and his colleagues was published on September 30, 2021, in *The Lancet Oncology*.

More information: Fred Saad et al, Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study, *The Lancet Oncology* (2021). [DOI: 10.1016/S1470-2045\(21\)00402-2](https://doi.org/10.1016/S1470-2045(21)00402-2)

Provided by University of Montreal Hospital Research Centre (CRCHUM)

Citation: Prostate cancer treatment: An encouraging combination therapy (2021, November 3) retrieved 21 May 2023 from <https://medicalxpress.com/news/2021-11-prostate-cancer-treatment-combination-therapy.html>

| |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p> |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|